1 Validation of multiplex steroid hormone measurements in prostate cancer using

2 plasma for multimodality biomarker studies

- 3 Gido Snaterse^{1,a}, Lisanne F van Dessel^{2,a}, Angela E Taylor³, Jenny A Visser¹, Wiebke Arlt³, Martijn P
- 4 Lolkema², Johannes Hofland^{1,*}
- 5 1. Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The
- 6 Netherlands
- 7 2. Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The
- 8 Netherlands
- 9 3. Institute of Metabolism and System Research, University of Birmingham, Birmingham, United
- 10 Kingdom
- ^aThese authors contributed equally to this work.
- 12 *Corresponding author
- 13 Address for correspondence: Johannes Hofland, Department of Internal Medicine, Erasmus MC, Rg5, Dr.
- 14 Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. Tel.: +31 10 704 0446.
- 15 E-mail: j.hofland@erasmusmc.nl
- 16
- 17 **Running title:** Multiplex steroid measurements in prostate cancer
- 18 Key words: Steroids, Androgens, Testosterone, CellSave, LC-MS/MS
- 19

21 General Abbreviations

- 22 ANOVA Analysis of variance 23 CRPC Castration resistant prostate cancer 24 CS CellSave Preservative tube 25 CTC Circulating tumour cell 26 ctDNA circulating tumour DNA 27 HC Healthy Control 28 LC-MS/MS Liquid chromatography tandem mass spectrometry 29 LOQ Limits of quantification 30 MS Mass spectrometry 31 MSP Mechanically separated plasma tube 32 MTBE Methyl-tert butyl ether 33 РС Prostate cancer 34 S/N Signal-to-noise 35 PBS-BSA phosphate-buffered saline with bovine serum albumin 36 **Steroid abbreviations**
 - 37 17OHP 17-hydroxyprogesterone
 - 38 A4 Androstenedione
 - 39 B Corticosterone
 - 40 DHEA Dehydroepiandrosterone
 - 41 DHT Dihydrotestosterone
 - 42 E Cortisone
 - 43 F Cortisol
 - 44 T Testosterone

45 ABSTRACT

46 Background

- 47 Steroid hormones are essential signaling molecules in prostate cancer (PC). However, many studies
- 48 focusing on liquid biomarkers fail to take hormonal status of these patients into account. Because
- 49 steroid measurements are sensitive to bias caused by matrix effects, thus assessing potential matrix
- 50 effects is an important step in combining ctDNA analysis with hormone status.

51 Methods

- 52 We investigated the accuracy of multi-steroid hormone profiling in mechanically-separated plasma
- tubes (MSP) and in CellSave Preservative plasma tubes (CS), that are typically used to obtain ctDNA. We
- 54 performed multiplex steroid profiling in samples obtained from ten healthy controls and ten castration-
- 55 resistant prostate cancer patients

56 Results

- 57 Steroid measurements were comparable between the MSP and serum tubes. A small but consistent
- 58 decrease of 11 18% compared to serum was observed in CS tubes, which was considered to be within
- 59 the acceptable margin. The minimally residual testosterone levels of castrate patients could be
- 60 sensitively quantified in both CS and MSP samples.

61 Conclusions

- 62 We validated the use of MSP and CS tubes for multi-steroid profiling by LC-MS/MS. The optimised use of
- 63 these samples used in clinical trials will allow us to gain further insight into the steroid metabolism in PC
- 64 patients.

65 INTRODUCTION

66 Prostate cancer is a steroid-hormone dependent disease where androgens play a pivotal role in the 67 evolution of the disease. Targeting the androgen signaling pathway through androgen deprivation 68 therapy (ADT) in locally advanced and metastatic prostate cancer is a highly effective way to inhibit tumour growth¹. However, tumour cells will eventually become resistant to these low androgen 69 70 concentrations and show disease progression. Resistance mechanisms include androgen receptor (AR) modifications, like mutations and overexpression^{2,3}, and changes in androgen biosynthesis and 71 metabolism, thereby increasing intratumoural androgen availability⁴⁻⁶. The continued importance of the 72 73 androgen signaling pathway in castration-resistant prostate cancer (CRPC) is underlined by the survival 74 benefits observed with second-line therapies such as the anti-androgen enzalutamide and adrenal steroidogenesis inhibitor abiraterone ⁷⁻¹⁰. Circulating steroid levels are measured to verify efficacy of 75 hormonal treatment and have a prognostic value in patients with prostate cancer¹¹⁻¹³. 76

The assessment of circulating steroid hormones relies heavily on sensitive, specific and accurate measurement techniques, especially at castrate levels. Liquid-chromatography tandem mass spectrometry (LC-MS/MS) combines multi-steroid profiling capabilities with superior sensitivity and specificity^{14,15} over older techniques^{16,17}, while maintaining high sample throughput^{18,19}. Extensive MSbased steroid panels have been successfully developed in recent years to improve the detection and diagnosis of disorders associated with abnormal steroid hormones concentrations²⁰⁻²³.

Steroid measurements are predominantly performed in serum samples. Previous LC-MS/MS studies have shown that steroids can be quantified reliably across different blood matrices²⁴⁻²⁶, but there are differences observed between plasma and serum, glass and plastic tubes, or when using tubes with different stabilizing agents or with gel-separators²⁴⁻²⁹. Consequently, alternative collection tubes and extraction methods must be validated before they can reliably be used for steroid profiling.

The use of CellSave (CS) tubes in population- and patient-based cohorts has grown as this specialised (cell-stabilizing' blood collection tube preserves both circulating tumour cells (CTCs) and cell-free circulating tumour DNA (ctDNA)^{30,31}. These biomarkers allow for the assessment of tumour cell genomic characteristics such as genomic instability in these patients³². These samples are now extensively collected in (cancer) biobanks and could potentially also be used to measure patient steroid profiles.

93 Mechanical separation methods of blood are similarly gaining popularity in clinical chemistry due to 94 their easy applicability compared to those that use a separation gel. The BD Vacutainer Barricor is a 95 mechanically-separated plasma (MSP) tube, and it has shown no obvious bias in steroid hormone 96 measurements versus a gel-based plasma tube in a single study³³, but this was confined to a select 97 number of five steroids, warranting further investigation.

98 Previous studies have identified matrix effects, interference caused by a contaminant from serum or 99 collection tube that leads to false high or low quantification, as a potential source of bias^{25,26,28}, and it is 100 therefore imperative to assess the quality of steroid measurements in CS tubes and MSP tubes. In this 101 study, we aimed to determine if plasma obtained with these tubes is suitable for multiplex steroid 102 profiling. To this end, we performed LC-MS/MS analysis on serum obtained with standard SST[™] II 103 Advance Vacutainer[®] tubes and plasma samples obtained with MSP and CS tubes from healthy control 104 (HC) subjects and patients with CRPC.

105 **RESULTS**

106 **Comparison of blood collection tubes**

Baseline characteristics of the study participants are shown in **Table 1**. Circulating steroid levels of 16 steroids were determined by LC-MS/MS in 10 HCs and 10 mCRPC patients in all three collection tubes. Quantification and concentration ranges for the steroids are reported in **Table 2**. Most steroids could be quantified in healthy controls at the level of the lowest calibration sample (0.25 ng/ml), with the exception of androstenedione (0.5 ng/ml), DHEA (1 ng/ml) and DHT (1 ng/ml). Serum DHEA values below the LLOQ were detected (HC: n =1, CRPC: n = 4) and excluded from further analysis.

The values observed in MSP samples were comparable to those found in serum for most steroids. The only exception was DHEA, which was higher (21.3 % \pm 32.9 % p<0.05) in the MSP samples than in serum (Figure 1). In CS samples, significantly lower concentrations compared to serum were observed for corticosterone (-16.2 % \pm 15.2 %, p<0.01), 17-hydroxyprogesterone (-11.0 % \pm 20.03 %, p<0.05), cortisol (-13.2 % \pm 13.0 %, p<0.001), cortisone (-14.4 % \pm 13.1 %, p<0.001), androstenedione (-18.4 % \pm 13.6 %, p<0.01). No significant differences were found for DHEA compared to serum.

Similar steroid concentrations between HC and mCRPC subjects were observed for corticosterone, cortisol and cortisone (**Figure 2**). Lower concentrations were observed for 17-hydroxyprogesterone, androstenedione and testosterone in mCRPC subjects. This was likely due to a combination of castration (testosterone) and age-related effects, as the mCRPC subjects were older than those the healthy control subjects.

Androgen levels in mCRPC patients are >10 fold lower than in healthy men due to ADT, requiring sensitive techniques to accurately measure residual androgens. The calibration series was expanded to include lower concentrations (0.01 - 0.25 ng/ml) to allow quantification of castrate testosterone levels.

Accurate quantification at 0.01 ng/mL was achieved for testosterone. Similar to the other steroids, lower testosterone concentrations compared to serum were detected in CS samples, but not in MSP samples, at normal HC concentrations (-11.5 % \pm 2.8 %, p<0.001) and at castrate concentrations (-16.9 % \pm 24.2 %, p<0.05) (**Figure 1**). Low signal-to-noise ratios limited the reliability of DHT quantification which could not be accurately quantified in the CRPC subjects with our assay.

132 Correlation of steroid measurements between matrices

133 The correlations between results obtained MSP and CS samples, respectively, compared to those 134 obtained in serum were determined by linear regression (Figure 3). For the DHT analysis only HC 135 samples were included. Corticosterone, DHEA and testosterone were normally distributed after log-136 transformation. Significant correlation (p<0.001) between both matrices and serum was observed for 137 corticosterone, 17-hydroxyprogesterone, cortisol, DHEA and testosterone. High correlation was also observed for cortisone and androstenedione, but with a more than 20% deviation from the optimal 138 139 slope (p<0.05) with the CS matrix: both 0.79x. The analysis also revealed a poor correlation for DHT between CS and serum ($R^2 = 0.60$) and between MSP and serum ($R^2 = 0.45$). 140

142 **DISCUSSION**

143 In this study, we investigated whether collected samples that are abundantly present in biobanks 144 obtained from PC patients such as mechanically separated plasma or CS-derived plasma are suitable for 145 multiplex steroid profiling by LC-MS/MS. We compared them to the current standard collection method 146 using SST[™] II Advance Vacutainers. We showed that measurements in MSP are equal to serum. When 147 collecting in CS tubes 11-18% lower concentrations were observed for all steroids. The Guideline on 148 Bioanalytical Method Validation (2011) of the European Medicines Agency advises that accuracy must be within 15 % of the nominal concentration and within 20 % at the LLOQ³⁴. The decreases observed for 149 150 most steroids in CS tubes using serum as a reference were within this acceptable range (Table 2). 151 Therefore, we conclude that CS samples are suitable for steroid profiling, which can be combined with 152 analysis of CTCs or ctDNA. However, caution is advised when interpreting results obtained in CS samples 153 against reference values that were obtained in serum, and direct comparison to samples collected in 154 other tubes should be avoided. Nevertheless, these findings may reduce patient burden and open up 155 the possibility to add detailed steroid profiling of large collections of biomaterial already collected for 156 ctDNA analysis.

157 In this study, most steroids could be quantified accurately within the range of the calibration series. 158 Most of the Δ 4-steroids, such as cortisol or testosterone, ionise more easily and so can be accurately 159 quantified at low levels (0.03 - 0.15 nM). This allows for the quantification of testosterone in mCRPC patients (typically <0.5nM)¹¹. Δ 5-steroids such as DHEA and saturated steroids such as DHT are poor 160 161 ionisers and quantification at lower concentrations is beyond the sensitivity of the mass spectrometer²². 162 Like testosterone, DHT levels are suppressed in castrated patients and the concentrations in these patients could not be accurately assessed. DHEA levels in men decline with age³⁵, and the mCRPC 163 164 subjects in this study were older than the HC subjects. Consequently, values below the LLOQ were

detected in four CRPC patients and were excluded from the analysis. Derivatization, for example to form an oxime, increases ionizability, and therefore sensitivity allowing low level quantification of Δ 5- and 5areduced steroids²². However, the derivatization method is not suited for routine clinical diagnostic measurements due to increased sample preparation time and cost. In addition to this, fragmentation produces multiple derivatives for some steroids adding to the complexity of the analysis.

170 Matrix effects and cross-reactivity are established sources of interference in steroid hormone profile studies with immunoassay and LC-MS/MS²⁴⁻²⁹. Previous studies have identified the type of blood sample 171 172 tube as a potential source of interference. MSP tubes like BD Vacutainer Barricor utilise mechanical 173 separation which makes them easily applicable, but the accuracy of steroid hormone measurements in these tubes has not been validated. One study³³ showed no differences to gel-based plasma tubes, but 174 175 these measurements were performed on a single platform with a limited number of steroids, namely 176 cortisol, DHEAS, oestradiol, progesterone, and testosterone. Our study shows that multi-plex steroid 177 quantification in MSP sample tubes is comparable to the reference serum tubes. We detected no 178 significant differences, with the exception of DHEA. This seemed to be largely driven by samples in the 179 HC group. Quantification of DHEA at low concentrations with LC-MS/MS remains a challenge as its structure contributes to poor MS ionization^{22,36}. This challenge could be overcome by using a more 180 181 sensitive mass spectrometer or with the use of derivatization. Prior to using MSP tubes for clinical 182 studies however, full validation looking at accuracy, precision and recovery is recommended.

CS tubes are optimised for the measurement of circulating nucleic acids or tumour cells^{30,31}. The use of this matrix for liquid biopsies has increased exponentially over the last years due to the successful genomic characterization of CTCs or free circulating nucleic acids, but no studies have investigated if CS tubes are suitable for quantification of circulating steroid hormone levels. Our experiments indicate that steroid measurements in CS tubes are affected by a mild bias which resulted in an approximate 10 – 20%

decrease compared to serum. We observed similar effects in both HCs and mCRPC subjects. CS tubes contain 300 μ l of Na₂EDTA anticoagulant as well as an undisclosed preservative to stabilise cells in the sample. Due to the presence of the Na₂EDTA there may be an inherent dilution of the sample, which amounts to approximately 3-4 % on a 7.5 – 10 ml volume. This dilution factor is insufficient to account for the difference in circulating steroid hormone levels however. Consequently, it is possible that other factors also contribute towards the observed difference.

This decrease was observed across a variety of different polarity steroids with different molecular weights. It is therefore unlikely that the preservative co-elutes with one of the steroids and suppresses the MS signal. Either there is an unidentified contaminant in the tubes which affects all steroids or the steroids themselves are being retained/bind to the tube itself. Steroids have been long recognised to stick to plastics³⁷, which may contribute to the lower values in CS samples.

199 Currently, CS tubes are most commonly utilised in oncological studies to obtain CTCs and ctDNA. 200 Hormonal treatment options in breast and prostate cancer involve potent suppression of oestrogens or 201 androgens. For example, inhibition of testicular steroidogenesis by ADT will typically lower testosterone levels by >90 $\%^{11}$. Interpretation of such changes is unlikely to be affected by the difference observed in 202 203 CS samples. Especially within the context of a single study the relative difference should affect all 204 samples identically as long as a single collection tube is used. As such, the observed difference is 205 acceptable for most clinical purposes, including the use of CS samples for steroid profiling in prostate 206 cancer patients. Steroid profiles and analysis of CTCs or ctDNA investigation will decrease costs and 207 reduce patient burden.

In conclusion, mechanically-separated plasma samples are suitable for steroid quantification, including
 castrate range of androgens. Similarly, CellSave samples are suitable for steroid measurements,
 although there is a consistent bias of –11-18% lower steroid hormone levels. Because of this, all samples

in a research study should be collected in the same sample tubes to avoid potential variation due toeffects from the tubes themselves.

213 MATERIALS AND METHODS

214 Subjects

215 At the Erasmus MC Cancer Institute in Rotterdam, The Netherlands, healthy controls (HCs) and patients 216 were included within study EMC-2016-761, which was approved by the medical ethical committee of 217 our institute. HCs were all adult male subjects. Patients were adult subjects with metastatic castration-218 resistant prostate cancer (mCRPC), treated with ADT. Patients were eligible to start treatment with or 219 were currently treated with second-line hormonal therapy (abiraterone with prednisone, enzalutamide 220 or apalutamide). For all subjects the following exclusion criteria were applied: 1) endocrine disease with 221 altered activity of the hypothalamic-pituitary-adrenal or hypothalamic-pituitary-gonadal axis; 2) the use 222 of medications, excluding those used to treat prostate cancer, that interfered with circulating steroid 223 levels or dysregulated the hypothalamic-pituitary-adrenal or hypothalamic-pituitary-gonadal axis. All 224 subjects provided written informed consent before any study procedure.

225 Samples

Blood was collected from HCs and mCRPC patients in SST[™] II Advance Vacutainer[®] (serum; BD, Franklin
Lakes, NJ, USA), Barricor Vacutainer[®] (BD) and CellSave Preservative (Menarini Sillicon Biosystems Inc,
Huntington Valley, PA, USA) blood collection tubes. All samples were processed within 96 hours after
blood collection. All tubes were centrifuged at 1,711*g* for 10 minutes at room temperature. Plasma from
CellSave tubes was subsequently centrifuged at 12,000*g* for 10 minutes at 4°C. Samples were stored at 80°C until extraction.

233 Steroid extraction

234 Calibration series (0.25 ng/ml - 500 ng/ml for HC, and 0.01 ng/ml - 500 ng/ml for mCRPC) were 235 prepared in phosphate buffered saline (PBS) with 0.1% bovine serum albumin (BSA) or in charcoal-236 stripped pooled human serum (Goldenwest Diagnostics, Temecula, CA, USA). Steroids investigated were 237 17-hydroxyprogesterone, androstenedione, cortisol, cortisone, corticosterone, dehydroepiandrosterone 238 (DHEA), dihydrotestosterone (DHT) and testosterone. The stripped-serum calibration series was used to 239 quantify all steroids with the exception of androstenedione, due to a high background signal in stripped 240 serum but not in PBS-BSA. An internal standard solution was prepared in methanol/water 50/50 with 241 equal concentrations (1 μ g/ml) of the following deuterated steroids: 17-hydroxyprogesterone-d8, 242 cortisol-d4, corticosterone-d8, DHEA-d6, DHT-d3, testosterone-d3. All steroids were obtained from 243 Sigma Aldrich, UK.

244 400 µl of sample was transferred to hexamethyldisilazane-treated (Thermo Fisher) glass tubes (VWR, 245 Amsterdam, The Netherlands). 20 µl of the internal standard solution was added and all samples were 246 thoroughly vortexed. Liquid-liquid extraction was performed by adding 2 ml methyl-tert butyl ether 247 (MTBE, Sigma Aldrich, Zwijndrecht, The Netherlands) to each tube and vortexing. The samples were left 248 at room temperature for 30 minutes to allow phase separation. The upper organic layer was transferred 249 and the MTBE was evaporated under nitrogen at 50° C. The samples underwent a second liquid-liquid 250 extraction with 2 ml MTBE. Samples were reconstituted in 125 µl LC-MS grade 50% methanol 251 (CHROMASOLV, Sigma Aldrich, Zwijndrecht, The Netherlands) before measurement.

252

253 LC-MS/MS

254 Steroid concentrations were measured by mass spectrometry (Xevo TQ-XS, Waters, Milford, MA, USA) 255 after separation on an ACQUITY uPLC (Waters) with a Waters HSS T3 column (2.1 mm x 50 mm, 1.8 μm, 256 Waters)³⁸⁻⁴³. The mobile phases consisted of water (A) and methanol (B) both with 0.1% formic acid and a 5-minute linear gradient was used (45 – 75% B) with a flow rate of 0.6 m l/min. The multiple reaction 257 monitoring settings and validation of these LC-MS/MS methods were previously reported^{38,42}. Steroids 258 259 were quantified against the linear calibration series relative to an internal standard and were only included in the final analysis if the calibration series R^2 was > 0.99 and appropriate lower limits of 260 261 quantification were reached. The lower limit of accurate quantification (LLOQ) was set to the lowest 262 calibration concentration that had a clearly defined peak and a signal-to-noise ratio > 10. Samples with 263 concentrations below the LLOQ were detectable, but not accurately quantifiable.

264 Statistics

LC-MS/MS raw data was processed using MassLynx (v4.1, Waters). Statistical analysis was performed using GraphPad Prism (Version 5). Normality of data was analysed with D'Agostino & Pearson's test. Comparisons of steroid hormone concentrations across the blood collection tubes were performed with repeat measurements 1-way ANOVA with post-hoc Dunnett's test. Correlations in hormone levels were determined by linear regression. Group concentrations and differences are shown as mean ± SD, unless specified otherwise. P values were considered significant if <0.05.

271 Data Availability

- 272 The datasets generated during and/or analysed during the current study are available from the
- 273 corresponding author on reasonable request.

274 References

- 275 1 Sharifi, N., Gulley, J. L. & Dahut, W. L. Androgen deprivation therapy for prostate cancer. *JAMA*
- **276 294**, 238-244 (2005).
- 277 2 Linja, M. J. *et al.* Amplification and overexpression of androgen receptor gene in hormone 278 refractory prostate cancer. *Cancer Res* 61, 3550-3555 (2001).
- Taylor, B. S. *et al.* Integrative genomic profiling of human prostate cancer. *Cancer Cell* 18, 11-22 (2010).
- 281 4 Stanbrough, M. *et al.* Increased expression of genes converting adrenal androgens to 282 testosterone in androgen-independent prostate cancer. *Cancer Res* **66**, 2815-2825 (2006).
- 283 5 Montgomery, R. B. *et al.* Maintenance of intratumoral androgens in metastatic prostate cancer:
- a mechanism for castration-resistant tumor growth. *Cancer Res* **68**, 4447-4454 (2008).
- 285 6 Mohler, J. L. *et al.* The androgen axis in recurrent prostate cancer. *Clin Cancer Res* **10**, 440-448
 286 (2004).
- 287 7 Scher, H. I. *et al.* Increased survival with enzalutamide in prostate cancer after chemotherapy. *N* 288 *Engl J Med* 367, 1187-1197 (2012).
- 289 8 de Bono, J. S. *et al.* Abiraterone and increased survival in metastatic prostate cancer. *N Engl J*290 *Med* 364, 1995-2005 (2011).
- 9 Fizazi, K. *et al.* Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
 N Engl J Med **377**, 352-360 (2017).
- Davis, I. D. *et al.* Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. *N Engl J Med* 381, 121-131 (2019).
- 295 11 Snaterse, G., Visser, J. A., Arlt, W. & Hofland, J. Circulating steroid hormone variations
 296 throughout different stages of prostate cancer. *Endocr Relat Cancer* 24, R403-R420 (2017).

- Sakamoto, S. *et al.* Higher Serum Testosterone Levels Associated with Favorable Prognosis in
 Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer. *J Clin Med* 8
 (2019).
- Attard, G. *et al.* Selective inhibition of CYP17 with abiraterone acetate is highly active in the
 treatment of castration-resistant prostate cancer. *J Clin Oncol* 27, 3742-3748 (2009).
- 302 14 Wang, C., Catlin, D. H., Demers, L. M., Starcevic, B. & Swerdloff, R. S. Measurement of total 303 serum testosterone in adult men: comparison of current laboratory methods versus liquid 304 chromatography-tandem mass spectrometry. *J Clin Endocrinol Metab* **89**, 534-543 (2004).
- 30515Taieb, J. et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas306chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 49,3071381-1395 (2003).
- Handelsman, D. J. *et al.* Performance of direct estradiol immunoassays with human male serum
 samples. *Clin Chem* 60, 510-517 (2014).
- 310 17 Krasowski, M. D. *et al.* Cross-reactivity of steroid hormone immunoassays: clinical significance

and two-dimensional molecular similarity prediction. *BMC Clin Pathol* **14**, 33 (2014).

- Taylor, A. E., Keevil, B. & Huhtaniemi, I. T. Mass spectrometry and immunoassay: how to
 measure steroid hormones today and tomorrow. *Eur J Endocrinol* **173**, D1-12 (2015).
- Monaghan, P. J., Keevil, B. G. & Trainer, P. J. The use of mass spectrometry to improve the diagnosis and the management of the HPA axis. *Rev Endocr Metab Disord* **14**, 143-157 (2013).
- Arlt, W. *et al.* Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary
 aldosteronism. *JCl Insight* 2 (2017).
- Arlt, W. *et al.* Urine steroid metabolomics as a biomarker tool for detecting malignancy in
 adrenal tumors. *J Clin Endocrinol Metab* 96, 3775-3784 (2011).

- Hakkinen, M. R. *et al.* Simultaneous analysis by LC-MS/MS of 22 ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum and
- 322 prostate tissue. J Pharm Biomed Anal 164, 642-652 (2019).
- 323 23 Storbeck, K. H. *et al.* Steroid metabolome analysis in disorders of adrenal steroid biosynthesis
 324 and metabolism. *Endocr Rev* (2019).
- Coburn, S. B. *et al.* Comparability of serum, plasma, and urinary estrogen and estrogen metabolite measurements by sex and menopausal status. *Cancer Causes Control* **30**, 75-86 (2019).
- Hepburn, S. *et al.* Sex steroid hormone stability in serum tubes with and without separator gels.
 Clin Chem Lab Med 54, 1451-1459 (2016).
- Raff, H. & Sluss, P. M. Pre-analytical issues for testosterone and estradiol assays. *Steroids* 73,
 1297-1304 (2008).
- Morovat, A. *et al.* Comparison of Bayer Advia Centaur immunoassay results obtained on samples
 collected in four different Becton Dickinson Vacutainer tubes. *Ann Clin Biochem* 43, 481-487
 (2006).
- Smets, E. M., Dijkstra-Lagemaat, J. E. & Blankenstein, M. A. Influence of blood collection in
 plastic vs. glass evacuated serum-separator tubes on hormone and tumour marker levels. *Clin Chem Lab Med* 42, 435-439 (2004).
- Schouwers, S. *et al.* Influence of separator gel in Sarstedt S-Monovette(R) serum tubes on
 various therapeutic drugs, hormones, and proteins. *Clin Chim Acta* **413**, 100-104 (2012).
- Rothwell, D. G. *et al.* Genetic profiling of tumours using both circulating free DNA and circulating
 tumour cells isolated from the same preserved whole blood sample. *Mol Oncol* 10, 566-574
 (2016).

- 343 31 van Dessel, L. F. *et al.* Application of circulating tumor DNA in prospective clinical oncology trials
 344 standardization of preanalytical conditions. *Mol Oncol* **11**, 295-304 (2017).
- 345 32 van Dessel, L. F. *et al.* The genomic landscape of metastatic castration-resistant prostate cancers
- reveals multiple distinct genotypes with potential clinical impact. *Nat Commun* **10**, 5251 (2019).
- 347 33 Fournier, J. E. *et al.* Evaluation of BD Vacutainer(R) Barricor blood collection tubes for routine
- 348 chemistry testing on a Roche Cobas(R) 8000 Platform. *Clin Biochem* 58, 94-99 (2018).
- 349 34 European Medicines Agency. Guideline on Bioanalytical Method Validation. (2011).
- 350 35 Kaufman, J. M. & Vermeulen, A. The decline of androgen levels in elderly men and its clinical and
 351 therapeutic implications. *Endocr Rev* 26, 833-876 (2005).
- 352 36 Keski-Rahkonen, P., Huhtinen, K., Poutanen, M. & Auriola, S. Fast and sensitive liquid 353 chromatography-mass spectrometry assay for seven androgenic and progestagenic steroids in 354 human serum. *J Steroid Biochem Mol Biol* **127**, 396-404 (2011).
- 355 37 Bruning, P. F., Jonker, K. M. & Boerema-Baan, A. W. Adsorption of steroid hormones by plastic
 356 tubing. *J Steroid Biochem* 14, 553-555 (1981).
- 357 38 O'Reilly, M. W. *et al.* A unique androgen excess signature in idiopathic intracranial hypertension
 358 is linked to cerebrospinal fluid dynamics. *JCl Insight* 4 (2019).
- 359 39 Buttler, R. M. *et al.* Comparison of 7 Published LC-MS/MS Methods for the Simultaneous
- 360 Measurement of Testosterone, Androstenedione, and Dehydroepiandrosterone in Serum. *Clin*
- 361 *Chem* **61**, 1475-1483 (2015).
- 362 40 van der Pas, R. *et al.* Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J
 363 *Endocrinol* 215, 403-412 (2012).
- Hassan-Smith, Z. K. *et al.* Gender-Specific Differences in Skeletal Muscle 11beta-HSD1 Expression
 Across Healthy Aging. *J Clin Endocrinol Metab* 100, 2673-2681 (2015).

- 366 42 Quanson, J. L. et al. High-throughput analysis of 19 endogenous androgenic steroids by ultra-
- 367 performance convergence chromatography tandem mass spectrometry. J Chromatogr B Analyt
- 368 *Technol Biomed Life Sci* **1031**, 131-138 (2016).
- 369 43 O'Reilly, M. W. *et al.* 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic
- 370 Ovary Syndrome. J Clin Endocrinol Metab **102**, 840-848 (2017).

371

373 Acknowledgements

- Funding for this project was provided by the Daniel den Hoed foundation.
- The authors thank the volunteers and patients who made this study possible.

376 Author Information

377 These authors contributed equally: Gido Snaterse and Lisanne F van Dessel.

378 Author Contributions

- 379 G.S. performed the LC-MS/MS experiments, data analysis, prepared figures/tables and wrote the
- 380 manuscript. L.F.D. collected the patient samples, performed data analysis, prepared figures/tables and
- 381 wrote the manuscript. A.E.T. oversaw the LC-MS/MS experiments and analysis of the data, and critical
- revision of the manuscript. W.A. was involved in interpretation of the data and critical revision of the
- 383 manuscript. M.P.L. was involved in the design of the work, collection of the samples and critical revision
- of the manuscript. J.A.V and J.H. were involved in the design of the work, interpretation of the data,
- 385 critical revision of the manuscript.
- 386 All authors reviewed and approved the final version of the manuscript.

387 Corresponding author

388 Correspondence to Johannes Hofland.

389 Conflict of Interest

- 390 M. P. L. is the recipient of grants of Sanofi, Johnson & Johnson and Astellas. Other authors did not
- 391 declare a conflict of interests.

Table 1 – Characteristics of healthy controls and castration-resistant prostate cancer patients

394 Abbreviations: mCRPC – metastatic castration-resistant prostate cancer

	Healthy Controls	mCRPC patients
N	10	10
Age (median (range))	32 (25 - 56)	64 (59 - 76)
Androgen Deprivation Therapy (n)		10
Leuproreline		4
Gosereline		4
Bilateral orchiectomy		2
Current second-line treatment (n)		6
Enzalutamide		3
Apalutamide		1
Abiraterone + Prednisone		1
Prednisone		1


Table 2 – Relative differences in CS and MSP tubes compared to SST™ II Advance Vacutainers.

- Relative differences are shown as mean ± SD. Statistical analysis was performed by repeated
- measurement 1-way ANOVA with post-hoc Dunnett's Test. *p<0.05, ** p<0.01, ***p<0.001.
- 399 Abbreviations: CS CellSave Preservative, DHEA dehydroepiandrosterone, DHT dihydrotestosterone,
- 400 HC Healthy Control, mCRPC metastatic castration-resistant prostate cancer, MSP mechanically
- 401 seperated plasma tube

	Healthy Controls (n = 10)		mCRPC			
			(n = 10)			
	Serum	CS	MSP	Serum	CS	MSP
	Range	Rel. Difference	Rel. Difference	Range	Rel. Difference	Rel. Difference
	nmol/L	mean (SD) %	mean (SD) %	nmol/L	mean (SD) %	mean (SD) %
Corticosterone	2.32 - 32.71	-20.08 (16.6) **	2.6 (11)	0.55 - 25.34	-12.3 (13.3) *	-2.8 (9.8)
17- hydroxyprogesterone	0.37 - 3.75	-14.4 (15.3) *	3.16 (16.26)	0.05 - 1.75	-7.6 (24.22)	-2.3 (16.58)
Cortisol	149.1 - 475.7	-13.7 (6.1) ***	-0.14 (3.5)	7.43 - 504.6	-12.7 (17.9) **	-1.3 (16.1)
Cortisone	36.35 - 79.4	-10.8 (6.3) ***	-2 (9.2)	0.1 - 80.81	-17.9 (17.2) **	-1.5 (10.5)
DHEA	0.69 - 36.14	-0.17 (18.8)	28.7 (46.6)*	<loq 1.7<="" td="" –=""><td>-17.7 (16.5)</td><td>6.0 (12.2)</td></loq>	-17.7 (16.5)	6.0 (12.2)
Androstenedione	2.33 - 6.05	-15.85 (13.5) **	6.9 (9.5)	0.48 - 3.19	- 21.2 (14.01) **	6.34 (10.4)
Testosterone	7.47 - 17.74	-11.48 (2.8) ***	0.82 (4.7)	0.06 - 0.78	-19.6 (28.2) *	-3.5 (33.3)
DHT	0.66 - 1.64	-11.26 (29.2)	-3.5 (30.4)	<loq< td=""><td><loq< td=""><td><loq< td=""></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""></loq<></td></loq<>	<loq< td=""></loq<>

Figure 1. CS and MSP samples compared to serum in healthy controls and mCRPC patients.


- 405 Steroid concentrations from serum, CS and MSP samples obtained from ten healthy controls and ten
- 406 mCRPC patients measured by LC-MS/MS. Relative difference of CS and MSP measurements compared to
- serum is shown. *p<0.05, **p<0.01, ***p<0.001, compared to serum matrix. Repeated Measurements
- 408 1-way ANOVA with post-hoc Dunnett's Test.
- 409 Abbreviations: CS CellSave Preservative, DHEA dehydroepiandrosterone, HC Healthy Control,
- 410 mCRPC metastatic castration-resistant prostate cancer, MSP mechanically seperated plasma tube



411

413 Figure 2 – Circulating steroid concentrations in healthy controls and mCRPC subject serum.

- 414 Steroid hormone concentrations in healthy controls (n = 10) and mCRPC patients (n = 10). Four patients
- 415 received no additional treatment, four received antiandrogens (enzalutamide (n=3) or apalutamide
- 416 (n=1)), one received abiraterone and prednisone and one received prednisone. Line and error represent
- 417 mean ± SEMs.
- 418 *Abbreviations*: 170HP 17-hydroxyprogesterone, A4 androstenedione, B corticosterone, DHEA –
- 419 dehydroepiandrosterone, CRPC castration-resistant prostate cancer, E cortisone, F cortisol, T –
- 420 testosterone



422 Figure 3 – Correlations between CS samples and MSP samples with serum.

Linear regression analysis between serum and CellSave measurements and between serum and MSP measurements in healthy controls and mCRPC patients combined. Corticosterone, DHEA and testosterone values did not pass normality testing (D'Agostino and Pearson), but did so after logarithmic transformation. *Abbreviations*: CS – CellSave Preservative Tube, DHEA – dehydroepiandrosterone, MSP – mechanically separated plasma tube.

